Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12000119 | PMC |
| http://dx.doi.org/10.1007/s12094-025-03867-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Short-Term Follow-Up Study on the Efficacy and Safety of Intravitreal Bevacizumab for Macular Edema Secondary to Retinal Venous Occlusions.
Cureus
July 2025
Ophthalmology, Great Eastern Medical School and Hospital, Srikakulam, IND.
Aim This study aimed to assess the short-term safety and efficacy of intravitreal bevacizumab in the treatment of macular edema (ME) secondary to retinal vein occlusion (RVO). Methods A prospective interventional study was conducted from July to December 2023, involving 30 patients with ME due to RVO. Intravitreal bevacizumab (1.
View Article and Find Full Text PDFBOP2-Comb: Bayesian Optimal Phase II Design for Optimizing Doses and Assessing Contribution of Components in Drug Combinations.
Ther Innov Regul Sci
August 2025
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
Background: Personalized cancer treatment using combination therapies offers substantial therapeutic benefits over single-agent treatments in most cancers. However, unmet clinical needs and increasing market competition pressure drug developers to quickly optimize combination doses and clearly demonstrate the contribution of each component when developing and evaluating new combination treatments.
Methods: We propose a Bayesian optimal phase II drug-combination (BOP2-Comb) design that optimizes the combination dose and evaluates the proof-of-concept as well as the contribution of each component in two seamless stages.
Background/aims: To describe the functional outcomes of patients with diabetic macular oedema (DME) non-responsive to bevacizumab switched to ranibizumab or aflibercept over 1 year and the demographic and anatomic predictors of these functional outcomes.
Methods: In a retrospective real-world cohort study, 76 consecutive patients with DME non-responsive to bevacizumab were reviewed at baseline and 12 months after switch to ranibizumab or aflibercept. Visual acuity (VA) and optical coherence tomography features such as central retinal thickness were assessed.
Which treatment modality offers the best outcomes for diabetic retinopathy? A systematic review and network meta-analysis.
Diabetes Res Clin Pract
September 2025
Department of Ophthalmology, Cardinal Tien Hospital, New Taipei City, Taiwan; School of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan. Electronic address:
Background And Objective: Diabetic retinopathy (DR) is a leading cause of preventable blindness globally, with proliferative diabetic retinopathy (PDR) and diabetic macular edema (DME) being the most vision-threatening complications. While panretinal photocoagulation (PRP) has been the traditional treatment for PDR, anti-vascular endothelial growth factor (anti-VEGF) therapies have emerged as effective alternatives. However, the comparative efficacy and safety of these interventions remain unclear.
View Article and Find Full Text PDFBLong-term results of branch retinal vein occlusion: 5-year follow-up.
Turk J Med Sci
July 2025
Department of Ophthalmology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Background/aim: This study aimed to report the 5-year outcomes of patients with newly diagnosed branch retinal vein occlusion (BRVO).
Materials And Methods: A retrospective review of patient charts was conducted. Data on central macular thickness (CMT), best-corrected visual acuity (BCVA), photoreceptor integrity, number of intravitreal (IV) antivascular endothelial growth factor (anti-VEGF) injections administered, and treatment regimen were assessed.